Key facts
- It has raised $1.4M; the latest was Seed Round ($1.4M) in Jul 2025.
- Notable investors include Triwise Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Punuokang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Punuokang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Punuokang Biotechnology
Developer of veterinary pharmaceuticals intended for the treatment of metabolic diseases in companion animals. The company offers targeted drug delivery systems, disease-specific compound screening, and proprietary formulations for conditions such as cardiac, renal, and oncological disorders, enabling the pet healthcare market to access specialized therapies with improved efficacy, reduced side effects, and compatibility with diverse animal physiology and clinical protocols.
- Sector
- Healthcare
- HQ
- Dongguan, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Punuokang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Punuokang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Punuokang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.